The National Cancer Institute is offering a grant to fund research on new treatments for adult glioblastoma, a type of brain cancer. The goal is to develop and test new drugs that can cross the blood-brain barrier, potentially leading to better treatments. This grant supports teams that can take a drug from early development through initial human trials.
Who it's for: This grant is for research teams that can develop and test new drugs for adult glioblastoma. Eligible applicants include universities, nonprofits, for-profit organizations, small businesses, and various government entities.
More details
Likely Disqualifiers
- Inability to conduct clinical trials
- Lack of preclinical study data
- Proposing agents not crossing the blood-brain barrier
- Lack of collaboration within a team
- Ineligible organization type
What You May Need
- Detailed research proposal
- Evidence of preclinical studies
- Plan for clinical trials
- Proof of ability to conduct IND studies
- Budget and justification
- Organizational documents
- Collaborative team structure
- Registration with NIH systems
- Letters of support
- Timeline for project milestones
Cautions
- Must be able to conduct Phase 0/1 clinical trials
- Requires a collaborative team approach
- Strict deadlines for application
- Must demonstrate drug can cross the blood-brain barrier
- Highly competitive funding
Generated from official source details for readability
Eligibility
Eligible Applicant Types
Additional Criteria
Eligible applicants include public and state institutions of higher education, private institutions of higher education, for-profit organizations, small businesses, nonprofits with or without 501(c)(3) status, state governments, city or township governments, county governments, special district governments, federally recognized Indian tribal governments, other Native American tribal organizations, and independent school districts.
Overview
This grant is for research teams that can develop and test new drugs for adult glioblastoma. Eligible applicants include universities, nonprofits, for-profit organizations, small businesses, and various government entities.
Likely Disqualifiers
- Inability to conduct clinical trials
- Lack of preclinical study data
- Proposing agents not crossing the blood-brain barrier
- Lack of collaboration within a team
- Ineligible organization type
Use of Funds
Funds can be used to develop and test new drugs for glioblastoma, covering stages from preclinical development to early clinical trials. This includes research activities, personnel, and necessary resources for drug testing.
Total Program Funding
$4,400,000
Expected Awards
4
Cost Sharing
Not Required
Important Dates
- Posted
- Aug 31, 2026
- Deadline
- Oct 1, 2026(19 days)
- Archive Date
- Nov 30, 2026
- Last Updated
- Aug 31, 2026
- Est. Award Date (AI estimate)
- Late Fall 2026
Application Checklist
- Register with NIH eRA Commons
- Prepare a detailed research proposal
- Gather evidence of preclinical studies
- Develop a clinical trial plan
- Create a comprehensive budget
- Assemble a collaborative research team
- Obtain letters of support
- Submit application by the deadline